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Abstract
Background: Musculoskeletal (MSK) pain from common conditions such as back pain and osteoarthritis is a major cause of
pain and disability. We previously developed a prognostic tool (STarT Back Tool) specifically for use in primary care to guide
the management of patients with low back pain. Prognostic stratified care models involve matching treatments to the patient’s
prognostic profile to support clinical decision-making in an effort to maximize treatment benefits, reduce harm and increase
health care efficiency. A logical next step is to determine whether a similar model of prognostic stratified care might also have
benefits for primary care patients with a much broader range of MSK pain presentations (back, neck, knee, shoulder and multi-
site pain).
Objective: The primary objective is to determine, in patients presenting with one of the five most common MSK pain
presentations in UK primary care, whether stratified care involving use of the Keele STarT MSK Tool to allocate individuals into
low, medium and high risk subgroups and matching these subgroups to recommended matched clinical management options, is
more clinically and cost effective compared to usual non-stratified primary care.
Methods: We are conducting a pragmatic, two parallel-arm (stratified versus non-stratified care), cluster RCT, with a linked
health economic analysis and mixed methods process evaluation. The setting is UK primary care, and the trial will include
approximately 24 average-sized general practices randomized (stratified by practice size) in a ratio of 1:1 (approx. 12 practices
per arm) with blinding of trial statistician and outcome data-collectors. The units of randomization are the general practices and
the units of observation are adults consulting for MSK pain without indicators of serious pathologies, urgent medical needs, or
vulnerabilities. Potential participant records will be tagged and individuals sent postal invitations using a GP point-of-
consultation electronic medical record (EMR) template. The intervention is supported by an EMR template housing the Keele
STarT MSK Tool (to stratify into low, medium and high-risk prognostic subgroups of persistent pain and disability) and
recommended matched treatment options. The primary outcome using intention-to-treat analysis is patient-reported pain
intensity, measured monthly over 6-months. Secondary outcomes include measures of physical function and quality of life and
an anonymized EMR audit will capture clinician decision-making. The economic evaluation will focus on the estimation of
incremental quality-adjusted life years (QALYs) and MSK pain-related healthcare costs. A mixed-methods process evaluation is
planned to explore a range of potential factors that might influence differences between trial arms, as well as to better understand
how stratified care is used and perceived by patients and clinicians involving quantitative analyses focussing on a priori
hypothesized intervention targets, and qualitative approaches using focus groups and interviews.  The sample size target is 600
patients per arm (1200 in total) from 24 general practices.
Results: Recruitment to the trial commenced on 18th May 2018 and ended on 15th July 2019, after a recruitment period of 14
months in 24 GP practices. It is anticipated that all follow-up and interview data collection will be completed by February 2020.
Conclusions: This study protocol describes the detail of the STarT MSK trial, which aims to investigate the clinical and cost
effectiveness of stratified primary care for patients with the five most common MSK pain presentations compared to usual non-
stratified care. The intervention was designed to improve patient outcomes including pain intensity, physical function and quality
of life, and also clinician decision-making in order to reduce treatment variability and improve adherence to best practice. This
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trial is the first attempt, as far as we know, at testing a prognostic stratified care approach for primary care patients with MSK
pain. The results of this trial should be available by the summer of 2020. Clinical Trial: ISRCTN15366334
(JMIR Preprints 23/01/2020:17939)
DOI: https://doi.org/10.2196/preprints.17939
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INTRODUCTION
Background
Musculoskeletal (MSK) pain from common conditions such as back pain and osteoarthritis is a major cause of
pain and disability. Estimates from the most recent global burden of disease suggest it is the leading cause of
disability adjusted life years (DALYS) in Western Europe and Australia [1]. Overall, it accounts for 6.8% of
global  DALYS,  comparable to  cancer  (7.8%),  ischemic heart  disease (5.2%) and mental  health  disorders
(7.4%). This burden is reflected in healthcare use, particularly in UK primary care where MSK pain accounts
for around one fifth of all consultations [2-4]. It also accounts for 8.8 million physiotherapy consultations and
over 3.5 million calls annually to emergency services [5]. Usual general practitioner (GP) care for MSK pain
typically  involves  a  long-term  management  approach  carried  out  during  short  10-minute  face-to-face
consultations during which patients are assessed and treated with advice, education and reassurance, analgesic
medication, referral for investigation(s), referral to other services offering conservative treatments such as
physiotherapist-led exercise, or referral to secondary care medical specialists such as orthopaedic consultants
and rheumatologists. For many patients, primary care clinicians should reassure them that their MSK pain is
not associated with serious underlying pathology, that the prognosis is usually good, and that further tests are
not indicated, combined with advice and support to help them stay active  [6]. However, evidence suggests
substantial variability in clinical practice, with treatment often not in line with best practice recommendations
in guidelines, particularly with respect to opioid medication and X-ray investigation [7].  
Due to the high prevalence of these common symptoms, MSK pain has overtaken mental health issues such as
stress  as  the  number  one reason why people  take time off  work in  Europe and the USA  [1].  The early
identification and improved management of those at risk of severe disabling MSK pain in primary care, where
the majority of these patients are managed, is therefore a high priority [8]. Patients with different MSK pain
presentations (e.g. back, neck, knee, shoulder or multi-site pain) share common prognostic factors  [9]. Co-
occurrence of MSK pain located in more than one body region is common  [10], with the risk of a poor
outcome increasing for those with multi-site pain  [11]. For example, the Chronic Pain Risk Score  [12] has
been shown to have predictive validity among patients with MSK pain in different body regions  [13-15].
However, previous prognostic questionnaires such as the Chronic Pain Risk Score and the Orebro MSK Pain
Screening Questionnaire [16] were not designed to guide primary care management and their use in primary
care clinical practice is uncommon. 
As  a  consequence,  we  previously developed a  prognostic  tool  (STarT Back Tool)  specifically  for  use  in
primary care to guide the management of patients with low back pain [17]. Prognostic stratified care models
involve matching treatments to the patient’s prognostic profile to support clinical decision-making in an effort
to maximise treatment benefits, reduce harm and increase health care efficiency [18]. The STarT Back Tool
consists  of  nine questions  summed into an index score.  It  utilises  cut-points  to  identify three prognostic
subgroups (patients at low, medium, or high risk of persistent disabling pain). In two previous UK studies,
stratified care for back pain, based on matching treatment to prognosis, led to superior clinical and economic
outcomes compared to best current practice and usual primary care  [19, 20]. The evidence suggested that
patients at low risk received less investigations and referral to secondary care, and by contrast patients at
medium or high risk were matched to treatments that could better  meet their needs,  leading to improved
outcomes. 
Rationale
A logical next step is to determine whether a similar model of prognostic stratified care might also have
benefits  for primary care patients with a much broader range of MSK pain presentations.  The five most
common MSK pain presentations in UK primary care are low back pain, knee pain, shoulder pain, neck pain
and multi-site pain [2]. In a research programme with four workpackages (the STarT MSK programme) our
team first developed and validated a new 10-item prognostic tool, the Keele STarT MSK Tool, to stratify
patients with the five most common MSK pain presentations into subgroups (those at low, medium and high
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risk  of  persistent  pain  and  disability)  [21].  Secondly,  we  agreed  evidence-based  recommended  matched
treatment options for patients in each subgroup following a systematic review [22], and expert consensus
process [23]. Thirdly, we conducted an external feasibility and pilot randomised trial with 524 patients from 8
general practices (4 intervention, 4 control) [24,25]. The pilot trial confirmed the acceptability of using a
stratified care approach in primary care consultations and also helped to refine our recruitment, retention and
sample size estimates, ahead of the main trial.  The findings informed the final wording of the self-report
version of the STarT MSK Tool, led to a Clinician Completed version of the tool, and allowed us to simplify
the recommended matched treatment options. All changes made to the main trial protocol following the pilot
trial  were  discussed,  shared  and agreed  with  the  trial  funder  the  National  Institute  for  Health  Research
(NIHR), the Trial Steering Committee and Data Monitoring Committee. 
Aims and Objectives
Primary Objective 
The primary objective of the STarT MSK main trial is to determine, in patients presenting with one of the five
most common MSK pain presentations in UK primary care, whether stratified care involving use of the Keele
STarT MSK Tool  to allocate individuals into low,  medium and high risk subgroups,  and matching these
subgroups  to  recommended  matched  clinical  management  options,  is  more  clinically  and  cost  effective
compared to usual non-stratified primary care. The primary clinical outcome is average pain intensity over the
past 2 weeks measured each month for 6 months.  
Secondary Objectives
The secondary objectives of the trial include:
1. Examining differences in secondary clinical outcomes, clinical decision-making and behaviours and health
economic outcomes at 6-months follow-up. 
 Patient  outcomes include  physical  function,  confidence to  manage  their  pain (pain self-efficacy),
psychological distress, fear avoidance beliefs, patient perceived reassurance from their clinician, pain
interference  with  sleep,  hobbies/leisure  activities,  pain  interference  with  work  and  daily  routine,
health related quality of life and patient satisfaction with care received. 
 Clinical decisions and behaviours of interest include identifying whether stratified care changes the
primary care management of MSK patients. We anticipate that primary care clinical management will
become more consistent for patients within each risk group and be more in line with stratified care,
where patients at low risk of persistent disabling pain are less likely to be referred for additional
healthcare  whereas  patients  at  medium or  high risk are  more likely to  be referred for  additional
healthcare in ways that match the recommended management options. Using the practices’ medical
record  data  we  will  examine  differences  between  the  trial  arms  in  clinical  decision-making  and
behaviours.
 Health economic evaluation will determine the cost-utility of stratified care in comparison to usual,
non-stratified care. A cost-consequence analysis will  initially be reported, with a subsequent cost-
utility analysis from a healthcare perspective to determine cost per quality-adjusted life years (QALY)
gained, calculated using EQ-5D-5L responses from the initial and 6-month questionnaires. A broader
costing perspective will  be considered in a sensitivity analysis,  taking into account NHS/Personal
Social Services costs and productivity costs associated with time off work. The outcome of interest for
the  economic  analysis  will  be  QALYs.  Additional  exploratory  analyses  will  consider  the  cost-
effectiveness of stratified care compared to usual non-stratified care for patients at low, medium and
high risk of persistent disabling pain.
2. Undertaking a process evaluation to explore how stratified care, as a complex intervention, interacts with
existing  patterns  of  service  organisation,  professional  practice,  and  professional-patient  interaction.  The
evaluation  will  use  mixed  quantitative  (e.g.  including  a  mediation  analysis)  and  qualitative  methods,
integrating  data  both  at  the  collection  and  analysis  stages,  in  order  to  generate  more  detailed  and
comprehensive findings. 
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METHODS
Study Design and Setting
The STarT MSK trial is a pragmatic, two parallel arm, cluster RCT, with a linked health economic analysis
and  mixed  methods  process  evaluation.  The  setting  is  UK  primary  care,  and  the  trial  will  include
approximately 24 average sized general practices with a total registered adult population of approximately
120,000. General practices will be randomised to either the stratified care intervention (approx. 12 practices)
or to continue with usual, non-stratified care (approx. 12 practices). The units of randomisation are the general
practices and the units of observation are adults consulting for MSK pain with one of the five most common
MSK pain presentations. The intervention in both arms of the trial will include an embedded template within
the general practice computer system which will ‘pop-up’ during the first relevant Read-coded MSK pain
consultation  within  the  specified  study  period  (termed  the  “MSK  consultation”;  this  may  be  the  first
consultation, or a repeat consultation for MSK pain). However, the content of the template will differ in the
two arms of the trial (see Figure 1); in the control arm it includes three questions; i) the eligibility of the
patient to be invited to participate, ii) the location/site of MSK pain for which the patient is consulting, and iii)
average MSK pain intensity in the past two weeks (primary outcome). In the intervention arm, in addition to
these three questions, the template also includes Keele STarT MSK Tool and recommended matched treatment
options (see Figure 2). 
A cluster RCT rather than an individual patient RCT was chosen for both scientific and practical reasons.
Stratified care is a new way of working and the tool, training and support is delivered at general practice level
(e.g. the computer template once installed will ‘pop-up’ on all the computers in the practice). Primary care
clinicians would likely find it difficult to behave differently towards individuals randomised to control and
intervention arms, and therefore the probability of contamination between the two arms would be high using
an individual patient randomised trial design. This trial can be thought of as a professional-cluster intervention
type  [26], in that the stratified care intervention involves changing the professional’s behaviour during the
consultation,  in  this  case  using a  prognostic  tool  and  matching patients  to  clinical  management  options.
Although the patient can opt out of data collection, the intervention is still likely to have an effect on them
since it involves introducing specific questions and recommendations about matched treatment options into
the consultation. 
Minimising Systematic Bias
The risk of selection bias, specifically of recruitment and participation bias, is a known concern in cluster
RCTs [27]. A number of steps have been taken to minimise this, which were tested in the pilot RCT, where we
observed no evidence of selection bias:
- The  initial  part  of  the  computer  template  to  help  identify  eligible  patients  is  automated  based  on
diagnostic codes entered during the consultation and operates in the same way in both arms of the trial.
- If the clinician deems a patient to be ineligible, they are asked to give a reason for this exclusion so that
these reasons can be compared across intervention and control arms. This process is monitored during
trial recruitment with monthly feedback provided to participating practices showing the frequency of
template non-completion, and the proportions of different reasons for ineligibility recorded. 
- Patients in both arms of the trial will receive identical study invitation packs comprising the same patient
information leaflet (which does not mention stratified care, only that the study seeks to better understand
how common aches and pains affect patients and how primary care can be improved), invitation letter,
questionnaire, and consent form for data collection, minimising the risk of patients in intervention or
control arms being more or less likely to participate (participation bias).
General practice recruitment and consent 
It is anticipated that an estimated eligible target population of approximately 5,000 patients will be identified
within  a  6-month  recruitment  window  from  approximately  24  average-sized  general  practices  (approx.
120,000 registered adults).  Practices  will  include those that  range in  size  (based on patient  list  size  and
number of GPs), and a range of settings (urban, semi-urban and rural). Practice eligibility criteria includes;
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those that use the EMIS Web clinical system (most commonly used electronic medical record system in the
UK); those proficient at using Read codes (diagnostic codes) during MSK consultations evidenced through an
audit of their recent Read coding behaviour; willingness to undergo the training and support sessions needed
to become familiar with the stratified care intervention; willingness to participate in anonymised aggregated
medical record audits of MSK consultations during the trial recruitment period; and willingness to engage
with the process evaluation.
The balance between scientific considerations and the need for consent is a known issue for cluster RCTs [26,
27]. Informed consent for practices to participate is formalised through written agreements led by the senior
GP partner in each practice acting as ‘guardian’ for patients in their care, following agreement with their team
to provide either usual care or stratified care for the period of the trial (dependent on random allocation). It is
anticipated that practices will actively recruit patients for approximately 6-months, with practice recruitment
periods staggered over a 12-month period. Reimbursement for practice time to recruit and participate in the
training is provided.
Individual Patient Participants
Potential  individual  patient  participants  will  consult  at  a participating practice with one of the  five  most
common  MSK  pain  presentations  (back,  neck,  knee,  shoulder  or  multi-site  pain)  as  determined  by  the
clinician at the point-of-consultation. 
Patient inclusion criteria: aged 18 years and over, registered at the practice during the recruitment period,
with a recorded relevant MSK pain Read code entered into the computer system (this may be the first, or a
repeat consultation), a completed study template, consent to study data collection, consent for research team to
have access to their medical record data, and completion of the initial postal questionnaire within 4 weeks of
the first mailing.
Patient  exclusion  criteria: those with  indications  of  serious  ‘red flag’ pathology (eg.  recent  trauma with
significant  injury;  acute,  red,  hot  swollen  joint;  suspected  fracture;  joint  infection;  cancer;  inflammatory
arthropathy such as rheumatoid arthritis; spondyloarthropathy, polymyalgia rheumatic; crystal disease (gout);
urgent medical care needs (e.g. Cauda Equina Syndrome); vulnerable patients (including any patients on the
‘severe and enduring mental health register’, or those who have a diagnosis of dementia, or those with a
recent diagnosis of a terminal illness, or those who have experienced recent trauma or bereavement, or those
nearing the end of their life); those unable to communicate in English (both in reading and speaking).
Patient recruitment for outcome data collection
As described above, an electronic computer template designed to automatically fire to help identify patients
will be installed on participating practice computer systems, when one of around 200 different MSK pain
related Read codes (symptom or diagnostic codes) is entered, as defined by Jordan et al. [2] and informed by
our pilot RCT. Clinicians will be trained to use this system, but it is already standard practice in NHS primary
care since 1985 for clinicians to use this standard vocabulary to record patient findings and procedures in
health and social care IT systems across UK. In the consultation, when an MSK related Read code in entered
onto the electronic medical record system, the trial specific template will be activated. Initially, it prompts the
clinician to notify eligible patients about the research study by reading the following: 
“Our practice is working with Keele University on a research study about ways to improve treatment for
common aches and pains such as back, neck, knee and shoulder pain. As you have consulted today for one
these conditions, we would like to share your contact details with the researchers so that they can send you
details of the study. Is that ok with you?"
Patients  who  do  not  give  this  consent  do  not  have  their  contact  details  shared  with  the  research  team.
Individuals who have previously asked not to be part of any research within the practice are given a Read code
that prevents the template from firing in the first place. Retention of identifiable patient data is restricted to the
limited period of invitation only, after which time the data of subsequent non-consenters to the trial will be
destroyed. Keele Clinical Trials Unit (CTU) operates this activity in compliance with the provisions of the
Data Protection Act (1998) and adheres to appropriate standards of governance and security as outlined by the
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Sponsor’s (Keele University) Standard Operating Procedures (SOPs). 
Practice  staff  supported  by  the  NIHR Clinical  Research  Network  (CRN)  where  possible,  will  regularly
(typically weekly) send the contact details of patients for whom the template has been successfully completed
to Keele CTU for the purpose of mailing patients their invitation letter,  using a secure NHS.net email to
transfer  data  including;  name,  address,  Read code  for  pain  site,  date  of  consultation,  and  EMIS patient
identification number. On a monthly basis the participating practices provide anonymised information about
the numbers  of  patients  for  whom the study template  is  activated and of  those how many are  not  fully
completed.  This  facilitates  the  provision  of  a  monthly  report  of  their  template  completion  rate  and  for
intervention  practices,  additional  detail  about  their  fidelity  to  choosing  recommended  matched  clinical
management options for patients at low, medium and high risk. 
Eligible participants (from both trial arms) will be sent identical study packs in the post containing: a letter
from the patient’s general practice introducing the study, a patient information leaflet (PIL), which describes
the study and includes instructions of what to do if they wish to take part, an initial questionnaire, including a
consent  form  to  record  consent  for  data  collection,  and  a  stamped  addressed  envelope.  The  following
mechanisms will ensure only eligible and appropriate patients are invited; a) a list of relevant exclusion Read
codes  (e.g.  recent  cancer  diagnosis)  will  be  used  to  automatically  prevent  the  template  from  firing,  b)
clinicians will be able to screen individual patients for their suitability at the point of consultation. 
In the initial questionnaire sent to patients, participants will provide their written consent for researchers to
use their data for this research. A study team member (blind to practice allocation) will support patients who
telephone with questions or who need additional support to complete their postal questionnaires, monthly
SMS texts or one-page questionnaires. The same set of MSK Read codes that trigger the automated template
was successfully used as the identification method in our pilot RCT. The electronic identification method is
designed to ensure the template ‘pop-up’ is only activated once per patient, so individuals can only be invited
once to participate in this study. Eligible patients who do not respond within two weeks to their initial study
invitation  will  be  contacted  again  with  another  study  pack.  Patients  who  do  not  complete  their  initial
questionnaire within four weeks of the initial mailing date will not be contacted again for follow-up data.
Patients who return their initial questionnaire and consent to further data collection will be included in the
study. The primary outcome (pain intensity) will be collected once a month for six months via SMS text or
one-page postal questionnaire (depending on participant preference). 
The procedures for reminders for the SMS text monthly communications are as follows: the initial contact will
be sent on the next Sunday afternoon that is closest to a calendar month following their initial questionnaire
mailing date. If there is no response to this initial contact, a reminder communication will be sent on Tuesday
afternoon  and  if  again  there  is  no  response  after  48  hours,  we  will  send  the  monthly  one-page  postal
questionnaire. On the second consecutive month we will repeat this procedure but if there is no response, in
addition to  sending the monthly one page postal  questionnaire,  a  study team member  will  telephone the
patient to establish what the problem is, seek to resolve it, provide appropriate support and collect the data
where possible. For those receiving the monthly one-page postal questionnaire, non-response after two weeks
will lead to another one-page postal questionnaire. Non-response on a second consecutive month will lead to a
study team member  telephoning the patient  to  establish what  the  problem is,  seek to  resolve it,  provide
appropriate support and collect the data where possible. Participants will also receive a 6-month follow-up
questionnaire to collect further outcomes. Non-responders to the 6-month follow-up questionnaire will be sent
a reminder postcard at two weeks, a full questionnaire two weeks later (i.e. at four weeks), and for those who
have not responded, a brief questionnaire will be sent after six weeks to collect key outcome measures. We
will try to collect minimum data over the telephone from participants at eight weeks where needed. These
follow-up methods have been used successfully in previous studies [28-31] including the pilot RCT.
Randomisation and blinding
Practices will be randomised in a ratio of 1:1 to intervention or control using stratified block randomisation
[32]  based  on  practice  patient  list  size  using  a  Keele  CTU  computer-generated  random  sequence  and
concealment by ensuring each practice has an anonymised code. The randomisation sequence/stratification
will  be  carried  out  by  the  senior  trial  statistician.  The  block  randomisation  will  follow  Keele  CTU’s
randomisation SOP and the data sequence will be held on a secure server. Blinding for individual clinicians is
not possible but any staff involved in the collection or database entry of patients’ outcome data will be blind to
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allocation. Access to the allocation sequence will be restricted to those with authorisation. Allocation will be
shared with the study team (except for the trial statistician and data entry staff who are to remain blind) who
will then arrange to inform each practice about their allocation. Data cleaning/checking through stage 1 ‘data-
freeze’ and stage 2 ‘data-lock’ reviews will be carried out by the trial statistician, thus maintaining blinding to
allocation. The Trial Steering Committee (TSC) will also be blinded to allocation unless it becomes absolutely
necessary to reveal allocation. The Data Monitoring Committee (DMC) trial statistician will be involved in
the allocation assignment, and therefore will  not be blinded throughout the study. These processes follow
recommendations for cluster trials  [27] to reduce selection bias where randomisation is prior to patient data
collection.
Interventions
Practice Recruitment Template Installation
Following confirmation that a practice is eligible and willing to take part, an initial setup meeting will be held
between the practice, study research team and a CRN member. This will take place for all practices in both
arms of the trial and will be followed by training sessions where the computer template will be installed and
demonstrated on the practice’s EMIS clinical system. Once the template is installed, the practice is ‘live’ and
potentially eligible participants will be identified in consultations. 
Intervention Arm
The recommended matched clinical management options are not new but summarise available evidence-based
options into those considered by expert consensus to be appropriate for patients at low, medium and high risk
of persistent pain and disability.
The STarT MSK stratified care approach has two components i) prognostic tool and ii) matched options: 
i) The Keele STarT MSK Tool (clinician completed version) © [is freely available at keele.ac.uk/startmsk] is
used in the patient consultation [21], and is supported by being embedded in the practice’s computer template,
dedicated training and support  sessions,  regular audit,  peer feedback and clinical  mentoring opportunities
using an evidence-based clinician support package to support clinician behaviour change [33]. The prognostic
tool has ten questions from which the patient’s score and subgroup (low, medium or high risk of persistent
pain and disability) are calculated.  
<insert Figure 2 here>
ii) Appropriate matched clinical management options based on an individual’s prognosis on the Keele STarT
MSK Tool will be displayed to support clinical decision-making. The matched clinical management options
were identified by an evidence synthesis [22], followed by three expert consensus workshops [23], during an
earlier phase of research and then further refined following the STarT MSK feasibility and pilot [24]. 
<insert Figure 3 here>
Per protocol treatment decision rules:
Patients at low risk will be considered to be treated “per protocol” if they receive only treatment options 1 or 2
(see Figure 3). Patients at medium risk will be “per protocol” if they receive any of options 3-6 (although
option 5 for specific pain sites only). Patients at high risk will be “per protocol” if they receive option 3 or any
options between 7-11.
It can be seen from Figure 3 that the matched options for patients at low risk include advice and education
(using printed materials where possible), over-the-counter analgesics and avoidance of MSK investigations
and referrals (where possible). Matched options for patients at medium risk, in addition to the low risk options
include GPs being encouraged to refer  patients  to  physiotherapy,  to  review their  pain medication and to
consider investigations where necessary. Matched options for patients at high risk, in addition to the medium
and low risk options include, consider atypical analgesia if neuropathic pain is present, referral to specialist
services  (e.g.  orthopaedics,  rheumatology  and  pain  clinics),  imaging  and/or  booked  reviews  to  manage
complex clinical factors such as co-morbidities, polypharmacy, and frailty. 
Clinician support to deliver stratified care
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The training and support sessions provided to intervention and control clinicians are designed to equip them
with  the  knowledge  and  skills  to  complete  the  study  recruitment  template  and  understand  the  study
inclusion/exclusion criteria. In addition, for intervention practices a 2-hour intervention training session will
be  provided.  This  includes  learning  about  previous  stratified  care  research  [19,  20],  the  rationale  for
developing this new intervention and for investigating whether it will benefit patients with a broader range of
MSK pain. Training will describe the aim to reduce unnecessary healthcare for patients at low risk, whilst
better targeting healthcare resources for patients at medium or high risk. Clinicians will have a demonstration
of how to use the new approach and have the opportunity to try it out and ask questions and explore how it
can be integrated into routine practice. The session will also include discussion and clarification about how the
approach differs from usual care and each of the recommended clinical management options. We will also
invite a representative from the local MSK physiotherapy service to the training sessions and discuss how best
to ensure that patient referrals to physiotherapy include a record of the index consultation and the patient’s
STarT MSK Tool risk group and agree the best method for physiotherapists to communicate with referring
GPs if they have a concern about a patient.  A feedback meeting will be held with all participating practices
(intervention and control) roughly 6 weeks after starting recruitment to discuss the report of their use and
completion of the study specific IT template. For intervention practices, additional feedback on their fidelity
to the recommended matched clinical management options will also be provided, comparing each clinician
with their colleagues in the same practice and with other clinicians in the trial (anonymised). Monthly email
feedback reports will be sent to participating practices. 
Physiotherapists  linked to  intervention practices  will  also have the opportunity to  attend a  short  training
session about the trial and be required to avoid treating patients from control practices for the period of the
trial to avoid contamination. However, other key features of physiotherapy care will be as similar as possible
for patients irrespective of whether they come from intervention or control practices, including: physiotherapy
waiting times, treatment session length and number, and the clinical grade of treating therapist. We will collect
these process data from physiotherapy services using a mix of usual clinical record data and standardised case
report forms for the study.
Control Arm
In the usual care control arm, patients will consult at their general practice, be assessed and receive advice and
treatment as usual (e.g. advice and education, medication, referral for investigations or tests, or referral to
other services such as physiotherapy, MSK interface clinics or secondary care specialists such as orthopaedics
and rheumatology), without the use of formal stratification tools. In order to keep the control arm as close to
“usual care” as possible, clinicians will be advised to follow their usual approach for responding to a patient’s
pain intensity rating for the presenting MSK problem. Asking a patient the intensity of their pain and where
their pain is coming from is common practice [30] and therefore should have little impact on the “usual care”
provided. 
Data collection 
There will be three different types of data collection: 
a) Individual patient data, collected from:  
i) the practices’ completed computer templates at the point of consultation
ii) initial and 6-month postal questionnaires to participants (full and minimum data versions)
iii) monthly SMS text or one-page postal questionnaire
b) Clinician decision-making and behaviours using data collected from medical records and case report
forms
c) Practice level anonymised aggregated data of MSK Read codes and template use
a) Individual patient outcomes 
i) General practice IT template
The first item on the template asks the primary care clinician to confirm if their patient gives consent to have
their contact details shared with the research team. If the answer is Yes, then the clinician will record the
location of the patient’s MSK pain. How this is answered determines which study letter and questionnaire the
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patient will be sent, as these are slightly different for patients with back, neck, knee, shoulder or multi-site
pain. The item reads: 
Please confirm the primary pain site the patient is consulting with today: 
Possible response options include: ‘back pain’, ‘neck pain’, ‘knee pain’, ‘shoulder pain’, ‘multi-site pain’, or
‘unable to complete template’ (which leads to the exit screen).
The third question on the template asks the clinician to record the patient’s MSK pain intensity by asking: 
How intense was your pain, on average, over the last 2 weeks? 
[Responses on a 0-10 scale, where 0 is “no pain” and 10 is “worst pain ever”]
ii) Initial and 6-month follow-up questionnaires
The initial and 6-month follow-up postal questionnaires are designed to collect information on descriptive
characteristics of the participants, pain-related characteristics and primary and secondary outcome measures
(see below). Patients are informed in their study invitation that they have been contacted because they recently
visited their general practice (the date of their visit will be given) for their MSK pain, which will be pre-
populated  in  the  letter  (e.g.  knee  pain,  shoulder  pain  etc.)  using  information  from  weekly  downloaded
template codes. 
Participants will  also be told that  it  is  important  they think about  their  <MSK pain> as they answer the
following question:
Thinking  about  your  (e.g.  neck)  pain:  Over  the  last  2  weeks,  on  average,  how intense  was  your  pain?
[Responses from 0 = no pain to 10 = worst pain ever]
iii) Monthly SMS text or one-page questionnaire for 3 items including the primary outcome 
In addition to the primary outcome (pain intensity), the monthly SMS text or one page questionnaire includes
two potential mediating variables using the following single items for psychological distress and self-efficacy
which are taken and adapted with permission from the validated Musculoskeletal Health Questionnaire [34]: 
“How much distress have you been experiencing because of your pain, on average, over the last 2 weeks? [0
= no distress to 10 = extreme distress]” 
“How confident have you felt about managing your pain by yourself e.g. medication, changing lifestyle? [0 =
not at all confident and 10 = extremely confident]”
b) Clinician behaviours via linked medical records 
Clinician decision-making and behaviours will be examined via a review of the practice computerised medical
records for all patients who give consent for this (at the end of the initial questionnaire). This will allow data
to be analysed from a)  individual  patient  outcomes  b)  the  initial  patient-clinician  consultation electronic
template, c) further aspects of their medical record over 6-months following the MSK consultation. Variables
of interest from the MSK consultation will include: the date of consultation, coded reason for the consultation,
MSK pain intensity and location, STarT MSK Tool (clinician completed version) individual items and total
score (intervention arm only), and information about the management decisions and other actions taken by the
clinician.  Other  clinical  behaviours  of  interest  are  described  in  the  outcomes  section.  The  information
collected on the patient’s risk subgroup and management options in the intervention practices will be audited
and fed back to clinicians at regular intervals,  allowing them to see how closely they have followed the
matched clinical management options. At the end of the trial we will also report the fidelity of clinicians in the
intervention practices in terms of completing the tool and choosing matched treatments options. The template
MSK pain intensity score will also provide the initial score for the primary outcome for participants in both
arms of the trial.
Physiotherapists  treating  patients  referred  from  participating  practices  will  complete  their  usual  clinical
records.  At  the  end  of  the  trial,  we  will  collect  details  about  the  physiotherapy  treatment  provided  for
consenting trial participants to compare between intervention and control. 
c) Practice level anonymised and aggregated data of MSK Read codes (n=~9,000).
Each participating general practice will  provide anonymised medical record data from potentially eligible
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patients for whom the template was activated through entry of an MSK Read code. We will compare: 
- the characteristics of those patients in which the template is activated with those who respond to the
initial questionnaire and provide individual level patient outcomes. The information examined will not
involve any patient identifiable data and will not be linked to any other data unless prior patient consent
has been. 
- aspects of clinical behaviours for 6-months following the index consultation to compare intervention and
control  practices  for  key treatment  processes  for  each risk subgroup.  For  example,  this  will  include
requests for: 
i)  prescriptions  (e.g.  categorised  into  such  as  simple  analgesics,  non-steroidal  anti-inflammatories
(NSAIDs), neuromodulators, muscle relaxants, corticosteroid injections and opioids)
ii)  referrals  (e.g.  categorised into physiotherapy/MSK interface services,  specialist  services  including
orthopaedics, pain clinics, and rheumatology)
iii) imaging (e.g. categorised into x-rays/MRI scans, MSK ultrasound scans and bone density scans)
iv) sick certifications or fit-notes (e.g. categorised into number per patient and mean length in days)
v) repeat MSK general practice visits
The collection of anonymised and aggregated medical record data is not uncommon within similar general
practice research studies that examine potential recruitment bias [35] or for intervention studies examining
clinician decision-making and behaviours during the consultation (e.g. POST cluster trial  [29] and SWAP
cluster trial [31, 36].
Patient and Public Involvement Engagement (PPIE)
This  study was  discussed  and shaped with  PPIE involvement  through dedicated  workshops  prior  to  the
funding submission. The PPIE group agreed with the importance of developing a more robust research base
for treatments that can improve the primary care management of MSK pain. Their discussions informed the
design and piloting of the text message system and one-page postal questionnaire, used to capture the primary
outcome of pain intensity, they also reviewed and improved the patient facing documentation for the study.
Members of the group have expressed an interest in being involved in the analysis of the qualitative data, and
it is intended to include them in that process.
Further PPIE meetings were held following the feasibility and pilot trial to identify improvements for the main
trial. Their recommendations included:
• Updating the invitation pack to provide greater clarity to patients about what is involved in taking part
in the trial
• Simplifying the consent form in the initial patient questionnaire 
• Removing the prize draw system we used for participants in the feasibility and pilot trial. This was
considered to potentially be confusing for patients and did not appear to lead to a higher response rate
to the questionnaires than those in similar research studies.  
Outcomes
Primary Outcome: 
The primary outcome for the trial is the patient reported clinical outcome of pain intensity, measured monthly
over 6-months. Pain intensity is a recommended outcome for trials of MSK pain  [37] and had strong face
validity among members of the PPIE group. In addition, analysis of our previous MSK cohort data confirmed
that this outcome is sensitive to change in this population. 
Secondary Outcomes:
Secondary  clinical  outcomes  captured  at  initial  and  6-months  stage  include:  body  site  specific  physical
functional measures, using the Roland-Morris Disability Questionnaire (RMDQ) for patients with back pain
[38], the Neck Disability Index (NDI) [39, 40] for patients with neck pain, the Shoulder pain and disability
index  (SPADI)  [41] for  patients  with  shoulder  pain,  the  Knee  Injury  and  Osteoarthritis  Outcome  Score
Physical Function Short-form (KOOS-PS) [42] for patients with knee pain and the Short Form 12v2 Physical
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Component Scale [43] for patients with multi-site pain. Other clinical outcomes will include patients’ risk of
persistent disabling pain using the Keele STarT MSK Tool, the MSK pain symptom severity and impact using
the  Musculoskeletal  Health  Questionnaire  [44] which  includes  measures  of  pain  interference  with  sleep,
physical activity level, hobbies/leisure activities, work and daily routine, and quality of life with items for
patients’ confidence to manage their pain (pain self-efficacy), emotional health, and understanding of how to
deal with their condition. We will also collect fear avoidance beliefs using the 11-item version of the Tampa
Scale of Kinesiophobia [45], and patient perceived level of reassurance from their clinician will be captured
using  the  Holt  and  Pincus  [46] reassurance  scale,  which  has  four  sub-scales:  information  gathering,
relationship  building,  generic  reassurance  and cognitive  reassurance.  Other  outcomes  will  include  health
related quality of life using the EQ-5D-5L to calculate quality adjusted life years (QALYs) in the health
economic evaluation [47] and single item questions to capture patient satisfaction with care received, receipt
of written education material from their clinician, and overall rating of change in their MSK pain since their
primary care consultation [48]. 
Baseline population descriptors:
To help describe the population recruited, additional baseline descriptors will capture: health literacy using the
Single Item Literacy Screener (SILS)  [49], episode duration of MSK pain by asking time since last whole
month free from this pain, age, sex, employment and their most recent paid job title (to calculate their socio-
economic status). 
Healthcare resource use:
Questions on additional healthcare resource use and patient borne costs including MSK pain-related hospital
inpatient  stays,  outpatient  attendances  (e.g.  to  physiotherapy),  other  NHS and private  practice  healthcare
appointments and over-the-counter medicines and treatment will be included in the 6-month questionnaire.
Work performance will be assessed through a single-item work presenteeism question, and time (days) off
work will be aligned to occupational information to ascertain cost of absenteeism. 
Table 1 summarises the patient reported data being collected. 
<INSERT TABLE 1 Here>
Process evaluation
A process  evaluation  is  planned to  explore  a  range  of  potential  factors  that  might  influence  differences
between trial arms, as well as to better understand how stratified care is used and perceived by patients and
clinicians. Following recent MRC guidance on process evaluations for complex interventions  [50] we have
designed  a  mixed  method  approach  [51].  This  will  use  quantitative  analyses  focussing  on  a  priori
hypothesised intervention targets, and qualitative approaches using focus groups and interviews. 
A key  aim  of  the  process  evaluation  is  to  better  understand  the  role  of  potential  intervention  targets
(mediators) on differences in outcomes between the trial arms [52]. The evidence from our previous stratified
care trial (for back pain, the STarT Back trial) suggested that the identification and targeting of psychological
distress among patients at  high risk led to improved outcomes  [53]. In addition,  a systematic review has
recently summarised available evidence and identified pain self-efficacy as another potential mediator  [54].
Evidence from the Keele IMPaCT Back study [20], which sought to implement our stratified care approach
for patients with low back pain consulting in general practice, suggested that important clinical behaviour
changes included more systematic identification of patients who are ‘at risk’ of persistent disabling pain who
need additional support (leading to more referrals to physiotherapy). After careful consideration by the trial
team, a number of potential treatment mediators have been identified a priori, including three potential factors
at the patient level, (i) reduction in levels of psychological distress measured each month with a single item,
(ii) increases in pain self-efficacy measured each month with a single item, (iii) increases in patient perceived
reassurance following primary care  consultation measured via  the  initial  questionnaire.  Changes in  these
potential  patient  level  treatment  mediators  will  be  examined  within  a  mediation  analyses  using  causal
modelling  techniques  (e.g.  structural  equation  modelling)  to  confirm  if  they  are  in  the  causal  pathway
explaining any observed between arm differences in outcome with results also examined at each subgrouping
level (low, medium and high). 
https://preprints.jmir.org/preprint/17939 [unpublished, non-peer-reviewed preprint]
JMIR Preprints Hill et al
In addition, one we have identified a number of a priori potential mediators at the level of clinical behaviour,
measured  using  the  medical  record  data,  including  the  proportion  of  patients  who  receive:  prescription
medications for MSK pain, referrals to other services (e.g. physiotherapy and secondary care specialists),
referrals for investigations (e.g. radiographs, MRI/CT scans, blood tests), sick certifications (fit notes), and
further MSK related consultations. We will test if there are significant differences in these behaviours between
intervention and control practices and whether any of these differences are associated with the results in terms
of patients’ pain intensity.
Sample size
In an average sized UK general practice (6,000 registered adults) we expect that about 800 potentially eligible
patients will  consult  with the musculoskeletal  pain sites of  interest  per year,  or  400 over  6-months.  The
feasibility and pilot trial showed that on average the template was activated 375 times over 6-months in each
practice, and clinicians fully completed it in 41% of cases (154 times or 6 times per week), leading to a letter
inviting the patient to participate in the data collection. From this, we expect 40% of patients invited will
return their initial questionnaire in the main trial, be eligible and consent to further data collection (or 62 over
6-months  in  one  practice).  However,  to  be  more  cautious,  given  general  uncertainty  in  data  and  in
generalisability  of  pilot  estimates,  we  have  conservatively  estimated  the  average  number  of  participants
recruited per practice within 6-months in the main trial to be around 33% of those invited (or n=50 in 6-
months or n=9 per month per practice). 
The trial is powered at 90% to test the hypothesis of overall superiority of stratified primary care versus usual
care based on an alpha of 5% (two-tailed) to detect a small ‘effect size’ (standardised mean difference) of 0.2
[55] in the primary outcome (pain intensity). An effect size of 0.2 was considered to be appropriate based on
information  from  the  feasibility  and  pilot  trial,  in  which  the  proportion  of  responders  in  the  three  risk
subgroups was: 32% at low risk, 55% medium risk, and 13% high risk. Our previous trial of stratified care for
patients with low back pain (the STarT Back trial) found an effect size of 0.3 and 0.4 in the primary outcome
(back pain-related physical function) in patients at medium and high risk respectively and so we have assumed
these standardised differences in this new trial [19]. Also, the minimal clinically important difference for the
NRS-pain scale in MSK pain has been reported to be 1-point [56], which equates to an effect size of about 0.4
relative to an expected SD of about 2.5 [55]. We expect that there would be little or no difference between
stratified care compared to usual care for patients in the low risk subgroup. Hence, through multiplying these
effects by the expected proportion within each of the subgroups,  the overall  effect  size of interest  is  0.2
(equating to an absolute mean difference of about 0.5 in pain intensity on a 0 – 10 scale).   
The  sample  size  calculation  takes  account  of  clustering  of  individual  participants  by  practice  and likely
participant  dropout  over 6-months  follow-up (inflationary effects  on sample size  requirement)  as  well  as
repeated measurements and adjustment for corresponding baseline pain intensity score (deflationary effects).
We have allowed for an ICC of 0.01 based on previous patient-level data from primary care trials [57] as well
as expected variation in recruitment per practice using a guideline coefficient of variation of 0.65 [58], and
together  with  an  expected  loss  to  follow-up  across  all  time-points  of  approximately  25%,  these  factors
combine  to  give  a  sample  size  inflation  factor  of  ×2.3  (based  on  an  average  cluster  size  of  about  50
participants per practice in 6-months). Correlation of data within 6 repeated measurements and correlation of
follow-up scores with baseline score are typically 0.7 and 0.5, respectively [59], which combine to give a
sample size deflation factor of ×0.5). The product of inflation and deflation effects results in a magnification
of 1.15 compared to a conventional, individual-patient, single follow-up comparison, whereby the sample size
requirement would be 525 per trial arm (or 1050 in total). The adjusted sample size target is therefore 600
patients per arm (1200 in total) from 24 general practices (12 per arm). 
Statistical reporting
Data  will  be  reported  according  to  the  Consolidated  Standards  Of  Reporting  Trials  (CONSORT 2010)
statement [60, 61], including extensions to cluster randomised trials [62] and pragmatic trials [63].
Final analysis will be carried out after all the data are collected, entered and cleaned according to Keele CTU
SOPs. A flow diagram will show the flow of participants through the trial including reasons for not taking part
and loss  to  follow-up (split  by  trial  arm).  For  trial  participants,  summaries  of  continuous  variables  will
comprise the number of observations used,  mean,  median,  SD, inter-quartile range as appropriate for the
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distributional form of the data (in total and split by treatment arm). Summaries of categorical variables will
comprise the number of observations used, and the number and percentage of observations in each category. 
Inferential analyses will include reporting of the main (point) estimate for the mean between-arm difference
(numerical outcomes) or odds ratio (categorical outcomes) along with 95% confidence intervals and P-values
(two-tailed). Odds ratios will also be converted to absolute risk differences (using the usual care prevalence as
the base-reference in any conversion).  Hypothesis tests  will  use a two-sided 5% significance level.  Main
analyses will be performed independently by the trial statisticians using the protocol and statistical analysis
plan agreed with the TSC. For any results discordance(s) if consensus agreement cannot be reached then a
third (independent) statistician will be asked to review and resolve any differences. 
Methods of analysis
Descriptive statistics: Baseline characteristics
The baseline demographics and clinical characteristics of general practices and individual participants will be
reported.  CONSORT guidelines  generally  do  not  recommend  statistical  significance  testing  of  baseline
imbalances between trial arms. However, a more recent publication suggests baseline testing of individual
level  characteristics  for  cluster  RCTs  to  examine  the  level  of  selection  bias  as  indicated  by  potential
imbalances in baseline covariates between arms [64]. 
Main analysis of primary outcome
To avoid any potential bias in the analysis, intention to treat (ITT) will be the primary analysis population
(including primary, and secondary outcomes) unless otherwise stated in the detailed Statistical Analysis Plan
(available from the authors).  This is defined as general practice-clusters (and affiliated participants) being
analysed as they are randomised regardless of the intervention. Data for individuals who withdraw consent to
participate in data collection will be included up to the point of withdrawal. Primary analysis will compare
mean difference in pain intensity scores between trial arms over 6-months follow-up using a hierarchical
linear mixed regression model evaluating repeated measures data at 1, 2, 3, 4, 5 and 6 months follow-up
(level-1) within individuals (level-2) and taking into account clustering of individuals within general practices
– the unit of randomisation (level-3). The analyses will be adjusted for age, sex and baseline pain intensity
score (recorded from the IT template at the point of consultation) at the individual-patient level, and general
practice  size.  This analysis  fulfils  the  ITT principle with analysis as  randomised and missing data  being
accounted for under the missing at  random assumption.  Although the primary analysis will  focus on the
‘average’ intervention effect across 1-6 months follow-up, we will also use treatment by time interaction terms
to evaluate between-arm differences in mean responses across each of the individual time-points of 1, 2, 3, 4,
5  and  6  months.  Model  fit  will  be  assessed  across  difference  covariance  structures  (unstructured,
independence, exchangeable, autoregressive) to ascertain the best-fit model that will be implemented (i.e. the
model that gives the lowest BIC, AIC and highest log-likelihood statistics). The monthly pain intensity scores
will be used but if, for any individual, the last monthly SMS/brief questionnaire response is missing but they
have  completed  the  corresponding  pain  intensity  question  in  their  returned  6-month  questionnaire  (if
completed within 20 days of the date of issue of their monthly SMS/brief questionnaire) then the available
pain  intensity  score  response  will  be  used  (as  the  6-month  score)  for  purposes  of  the  primary  outcome
evaluation. 
Analysis of secondary outcomes
Analysis of secondary outcomes will similarly be carried out following the ITT approach and using a linear
mixed  model  for  numerical  outcomes  and  generalised  mixed  logistic  models  for  categorical  outcomes
(adjusted for age, sex, baseline pain and corresponding baseline score (where applicable) at the individual-
patient  level,  and  general  practice  size).  For  monthly  follow-up  measures  of  distress  and  confidence  in
managing pain, the analysis will follow that of the primary analysis with initial focus on ‘average’ scores over
the 6-months of follow-up and then the time-specific between-arm estimates. The focus of the other secondary
measures is on 6-month follow-up data only, with the exception of perceived reassurance which is captured in
the baseline questionnaire.
Sensitivity analysis of primary outcome
A sensitivity analysis will be carried out using a complier average causal effect analysis (CACE) to provide an
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unbiased estimate of intervention effect for patients treated according to the stratified care protocol i.e. for the
intervention arm ‘protocol’ is taken as clinical management in line with the recommended matched treatment
options  for  each  risk  subgroup.  CACE analysis  will  be  performed  using  a  2-step  instrumental  variable
regression modelling approach where the first step relates to model prediction of ‘compliance’ (at level 2
(individual patient level)) using trial arm only as a fixed-effect predictor and practice and participant IDs as
random-effects,  and  the  second  step  estimates  the  between-arm  difference  in  outcome  (‘average’ pain
intensity) based on predicted compliance – the endogenous (instrumented)  variable (from the first step) and
the exogenous (instrumental) variables of trial  arm, age, sex and point-of-consultation pain score using a
mixed effects model as used in the primary analysis. 
Subgroup exploratory analysis of primary outcome
Subgroup  exploratory  analysis  of  the  primary  outcome  (‘average’ pain  intensity)  will  be  carried  out  by
modelling  intervention  arm-interaction  terms  within  the  regression  models  for:  (i)  risk  subgroups  (low
(reference category), medium and high risk); (ii) single MSK pain (reference) site versus multi-site pain; (iii)
pain site  (back (reference),  shoulder,  knee,  neck).  Subgroup analysis  will  be  performed regardless of the
results of the primary analysis. The mean between-arm difference (and 95% CI and P-value) will be computed
for each subgroup comparison and visually displayed via a forest plot. The main focus will be on the ‘average’
pain intensity rather than on 3-way interactions of intervention-subgroup-time – but the 3-way interaction
results will also be examined (and descriptive results produced by subgroup). 
Exploratory mediation analyses
If there is a significant between-arm difference in the primary outcome (overall pain intensity) then we will
carry out  exploratory mediation analysis by structural  equation modelling to examine (i)  which potential
mediators are ‘causal’ in effect; (ii) if psychological mediators (psychological distress or pain self-efficacy in
months 1-5) are on the causal pathway for effect; (iii) if patient perceived reassurance mediates direct/indirect
associations of 6-month pain intensity outcomes.   
Evaluation of process outcomes
Process outcomes will be evaluated through comparison of aggregated anonymised data at the level of the
participating general practices, by examining, for example, re-consultation rates for MSK pain over 6-months
and  referral  rates  to  other  services  between  practices  in  the  stratified  care  versus  usual  care  arms.  In
intervention practices, we will also investigate the proportions of patients for whom the electronic template is
completed, and matched clinical management options are selected overall and by risk subgroup. 
A descriptive analysis will  be undertaken of physiotherapist  data by intervention arm (eg.  waiting times,
number of treatment sessions, clinical grade of treating physiotherapist).
Examination of bias
Selection bias  will  be  examined through scrutiny of comparability  of  recruitment rates  per  trial  arm and
comparability in general  practice and participant  characteristics.  Further,  a  comparison will  be performed
examining the characteristics of patients in which the electronic template is activated but who did not take part
in the data collection (non-participants) with those who did participate in terms of practice distribution, pain
intensity scores, location of MSK pain, and (within the intervention arm) the proportion of patients at low,
medium and high risk of persistent disabling pain (from the practice consultation IT template). Both crude
descriptive and inferential statistics will be reported.
Differential attrition between trial arms will be examined and reported descriptively: frequencies for responses
by trial  arm will  be recorded in the descriptive tables.  We will  compare baseline socio-demographic and
clinical  variables  and (for  response ≥1)  monthly NRS-pain intensity scores across level-of-completion of
NRS-pain intensity (level of completion = 0 to 6, where 0=non-response, 1=responded once and 6=responded
to all six monthly follow ups) to ascertain whether pattern of missingness is likely to be ‘missing completely
at random’,  ‘missing at random’ or ‘not missing at random’. If the overall  follow-up rate of the primary
outcome is over 5% different between trial arms and the pattern of missing data is ‘missing at random’ then
we will undertake a multiple imputation or MI (via chained equations) analysis inclusive of baseline variables
that are observed to be statistically associated with follow-up response. Further, if the pattern of missingness is
seen to suggest that it is non-ignorable, the MI sensitivity analysis will address missing data imputations with
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additionally incremented or reduced value corresponding to the overall baseline SD (thereby mimicking the
non-ignorable pattern). 
Health Economics
The health economics analysis will determine the cost-effectiveness of stratified care in comparison to usual,
non-stratified care over 6-months. A cost-consequence analysis will initially be reported, describing all the
important results relating to costs and consequences. Subsequently cost-utility analysis will be undertaken
from an NHS/Personal Social Services (PSS) perspective to determine the cost per additional QALY gained. A
broader costing perspective will be considered in a secondary analysis, taking into account NHS/PSS costs,
private MSK-related healthcare costs and productivity costs associated with time off work.  
Costs
Resource  use  information  will  be  obtained  on  primary  care  consultations  (eg.  general  practitioners  and
practice  nurses),  secondary  care  consultations  (e.g.  hospital  consultants,  physiotherapists),  prescriptions,
hospital-based procedures (eg. diagnostic tests, injections, and investigations), length of inpatient stays, and
surgery.  Patients will  be asked to distinguish between UK NHS and private provision.  Cost  data will  be
collected via participant questionnaire at 6-months. Unit costs will be obtained from standard sources and
healthcare providers including the British National Formulary (BNF), Unit Costs of Health and Social Care
and NHS Reference costs  [65-67].  Given that  MSK pain is  associated with significant  lost  productivity,
information will also be collected from participants on occupation status, time off work related to their MSK
problem and reduced work performance (presenteeism). This will enable the calculation of productivity costs,
allowing analysis from a broader societal cost perspective. The average wage for each respondent will be
identified using UK Standard Occupational Classification coding and annual earnings data for each job type
[68]. 
Outcomes
The  outcome  of  interest  for  the  economic  analysis  is  quality-adjusted  life  years  (QALYs)  and  will  be
generated from participant responses to the EQ-5D 5L questionnaire at baseline and at 6-months follow-up.
The crosswalk value set will be applied to patient responses to obtain utility scores, in line with current NICE
recommendations.
Data analysis
The cost-utility analysis will be carried out on an ITT basis, with the aim of estimating the difference in costs
and QALYs between the stratified care and usual, non-stratified care arms. Missing EQ-5D 5L and cost data
will be imputed using MI techniques [69] in order to ensure that all trial participants are included in the final
analysis.  For each participant, a QALY score over the 6-month follow up period will be estimated using the
area under the curve approach [70]. Imbalances in baseline utility (EQ-5D 5L) scores between the stratified
care and usual non-stratified care arms will be controlled for using a regression approach [71].
Total healthcare costs over the study period will be calculated by multiplying the resource items used by the
respective unit cost and summing over all items. Differences in mean costs and QALYs between the stratified
care  and usual  non-stratified care arms will  be  estimated.  The data  for  costs  is  likely to  have a skewed
distribution,  therefore,  a  non-parametric  comparison  of  means  (e.g.  bootstrapping)  will  be  undertaken to
estimate 95% confidence intervals around costs.  
Due to the nature of the trial, methods are required to address clustering in both costs and outcomes, and to
recognise correlation between individual- and cluster-level costs and outcomes. Methods currently suggested
in the health economics literature are multilevel models (MLM) and the 2-stage non-parametric bootstrap
(TSB) [72]. For the base case scenario, MLM will be used to estimate differential costs, differential QALYs
and incremental net benefits. The analysis will also allow us to control for covariates. The robustness of the
results will be explored using sensitivity analysis. This will explore uncertainties in the trial data itself as well
as  the  methods  employed  to  analyse  the  data.  A cost-effectiveness  acceptability  curve  (CEAC)  will  be
constructed to assess the probability that stratified care is effective at different willingness-to-pay thresholds.
In order to estimate productivity costs, self-reported days off work will be multiplied by the average wage
rate. The analysis will use the human capital approach. 
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Planned sensitivity analysis will include: 1)   a complete-case analysis as an alternative to using an imputed
dataset  2)  a  broader  societal  perspective  3)  Additional  exploratory  analyses  that  will  consider  the  cost-
effectiveness of stratified care versus usual non-stratified care for patients in the low, medium and high risk
subgroups separately. All analyses will be performed using performed using Stata 15 software. 
Linked qualitative study
Theoretical framework
Two theoretical frameworks will underpin the evaluation; firstly, the COM-B model [73], which offers a way
of  understanding  behaviour  in  the  context  of  complex  interventions,  around  three  key  determinants:
capability – the psychological or physical ability to enact the behaviour; opportunity – the physical and social
environment  that  enables  the  behaviour;  and  motivation –  the  reflective  and automatic  mechanisms that
activate  or  inhibit  behaviour.  Second,  Normalisation  Process  Theory  (NPT)  provides  a  framework  for
understanding how/why some new healthcare interventions are accepted and taken up whilst others are less
successful [74].  Both frameworks emphasise the broader socio-political contexts in which health behaviours
and practices are situated,  and the importance of taking these contexts into account in understanding the
adoption of new interventions [74, 75].  
Aim
To understand the ways in which stratified care is perceived and operationalised, from the perspectives of
healthcare professionals and patients, taking into account individual, local and national contexts. 
Objectives
i) Identify the acceptability and impact on the consultation of using the clinician completed version of the
Keele STarT MSK Tool, and the extent to which the matched treatment options are viewed as being in
line with clinical judgements on best practice
ii) Understand  the  impact  of  stratified  care  on:  i)  individual  clinicians,  ii)  general  practice  and
physiotherapy services, iii) inter-professional and professional-patient communication, and iv) patients
at low, medium and high risk 
iii) Document any variation in experiences or views across different practices and services in the trial.
Methods
An iterative,  mixed methods approach will  be adopted [51,  76],  with the quantitative data informing the
qualitative data collection, and analysis from both informing the overall findings and conclusions.  Data will
be drawn from:
Clinicians: GPs and physiotherapists involved in delivering stratified care will be invited to participate in up
to 3 separate focus groups held at approximately 4 GP practices Where clinicians are unable to attend focus
groups,  arrangements will  be made for individual  interviews.  Initial  focus groups/interviews will  explore
clinicians’ views and experiences of delivering stratified care during the course of the trial. Follow-up focus
groups/interviews will be conducted at a later stage once trial results are available, to explore views on the
trial results and, depending on these results, discuss potential implications for practice, policy and service
provision beyond the trial. 
Patients:  one-to-one semi-structured interviews will be conducted to explore individual patient experiences.
Patients at low risk will be interviewed approximately 2 months after their index primary care consultation,
whereas patients at medium and high risk will be interviewed at approximately 4 months. This timescale will
allow for  participants to reflect on their experiences of clinical management (including time to access any
treatments), communication with the clinicians involved in their care, and their healthcare resource use over
time. 
Sampling 
Clinicians and patients will be sampled from the stratified care arm of the trial. GPs directly involved in the
trial will be identified based on diversity of practice characteristics, including size and geographic location. A
sample of physiotherapists in linked participating services will also be invited to participate. Patients will be
https://preprints.jmir.org/preprint/17939 [unpublished, non-peer-reviewed preprint]
JMIR Preprints Hill et al
purposively sampled from baseline questionnaire responses to capture diverse characteristics, such as pain
scores and health related quality of life, risk subgroup, co-morbidity, age, sex and socio-economic status. 
Sample size of qualitative study
Data collection will continue until saturation is reached, defined as ‘informational redundancy’‒ the point at
which  additional  data  no  longer  offer  new  insights  [77].   We  estimate  around  20-30  clinicians  and
approximately 20-30 patients will be required.
Recruitment to qualitative study
Clinicians  will  be  informed  that  as  part  of  their  participation  in  the  trial,  they  may  be  approached  to
participate in focus groups or interviews. Additional information explaining confidentiality, anonymity, data
storage and archiving will be distributed ahead of each focus group/interview, and individual written consent
obtained prior to the start of the discussion. 
Patients will be informed that, as part of their participation in the study, they consented to further research
contact. An invitation letter and detailed interview information leaflet will be mailed to the patient, and after
2-3 days a researcher will telephone the patient to check if they are willing to participate and, if so, make
arrangements  for  the  interview.  Interviews  may  be  face-to-face  or  by  telephone,  based  on  participant
preference, and will be arranged at a time/location convenient for the participant. Once an interview has been
arranged a confirmation letter will be sent. Written consent will be obtained at the start of the interview, or
audio-recorded if the interview is via telephone and checked again at the end. Interviews are estimated to last
approximately one hour.  
Trial management, Study Administration and Data Storage 
The Trial Manager assisted by the Study Coordinator will oversee the day to day running of the trial. General
practice staff assisted where necessary by the CRN will download details of patients who have a completed
template  (name,  address,  the  MSK pain  site,  date  of  MSK consultation  and EMIS patient  identification
number) on a weekly basis from each practice. Practice staff will arrange transfer of patient details to the
dedicated research administrator in Keele CTU using nhs.net to nhs.net transfer for mailing of the study invite
pack to potential participants. A unique study number will be applied to each potential participant. On return
of a completed initial questionnaire, details will be entered into the research database to ensure no unnecessary
reminders are sent. Details of informed consent will be stored on the research database including participants’
names and contact details. In this database participants will be primarily identified by study number. Data will
be entered into the research database by trained members of the administrative team who will be blinded to
general practice allocation. Access to the database will be restricted to those members of the team that require
access. The coding schedule for the questionnaires will be used to inform database design and to facilitate data
entry. Details of data entry accuracy will be kept by the research data management lead and trial statisticians
and reported. 
Any  requests  for  access  to  the  anonymised  data  will  follow  our  data  sharing  procedure.  Requests  for
anonymised data  will  be  reviewed by our  Data  Custodian and Academic Proposals  Committee.  The full
statement on data sharing can be found at  www.keele.ac.uk/pchs/datasharing. All information will be held
securely and in strict confidence. Each person in this study will be given a study number so that data from the
study will not have any identifiable information, such as names and addresses, and cannot be traced. On this
basis, these anonymised data will be kept electronically and may be used in other research studies.
Clinical Governance Issues 
To ensure responsibility and accountability for the overall quality of care received by participants during the
study period, clinical governance issues pertaining to all aspects of routine management will be brought to the
attention  of  the  TSC and,  where  applicable,  to  individual  participating  practices  or  NHS services.  One
potential  issue  is  that  GPs  in  the  intervention  arm  may  feel  that  the  recommended  matched  clinical
management options are not appropriate for an individual patient, in which case they will need to choose a
treatment that is not amongst the recommended options. The clinician training sessions will make it clear that
despite being part of a clinical trial clinicians retain the responsibility to provide appropriate care to their
patients. Clinicians will be encouraged to report to the research team where there are consistent difficulties
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with the stratified care intervention.
Statement of Indemnity and Trial Sponsor
Keele University has in place Clinical Trials indemnity which provides cover to the University for harm which
comes about through the University’s, or its staff’s, negligence in relation to the design or management of the
trial  and  may alternatively, and at  the  University’s  discretion  provide  cover  for  non-negligent  harm  to
participants. The NHS has a duty of care to patients treated, whether or not the patient is taking part in a
clinical  trial,  and the NHS organisation (general  practices  and other  services  involved)  remain liable  for
clinical  negligence  and  other  negligent  harm  to  patients  under  this  duty  of  care.  The  Sponsor  (Keele
University) is responsible for trial initiation management and financing of the trial as defined by Directive
2001/20/EC. 
Oversight/Trial Monitoring
Trial  Management  Group (TMG):  comprising  of  the  CI,  AI,  Keele  CTU staff,  and  other  key  trial  team
members have responsibility for the clinical set-up, ongoing management, promotion of the trial, and for the
analysis and interpretation of results.  Specifically the TMG are responsible for the (i) protocol completion,
(ii) study document development, (iii) obtaining Health Research Authority (HRA) approval, (iv) completing
cost  estimates and project  initiation,  (v) facilitating the TSC and DMC, (vi)  reporting of serious adverse
events,  (vii)  monitoring of  recruitment,  intervention and follow-up procedures,  (viii)  data  collection,  and
database development. The group will meet on a regular basis, typically monthly, throughout the trial. The
trial does not incorporate any a priori stopping rules, and hence no planned interim analysis of the outcome
measures collected in the trial will be carried out. 
Financial Arrangements
Clinicians  participating  in  the  focus  groups/interviews  will  receive  a  reimbursement  of  their  time  using
standard professional rates.  Patients participating in an interview will be given a £10 Love to Shop gift token
by  way  of  thanking  them  for  their  participation  and  will  only  receive  remuneration  for  travel  if  they
participate in an interview at a site other than their home.
Serious Breaches of the Protocol and GCP
Keele CTU has systems in place to ensure that serious breaches of GCP are picked up and reported. A “serious
breach” is a breach which is likely to effect to a significant degree: the safety or physical or mental integrity of
the participants of the trial; or the scientific value of the trial. All protocol deviations or breaches of GCP will
be recorded and reported to the Sponsor according to the relevant SOP.
Serious Adverse Events
Serious  adverse  events  (SAE)  include  death,  hospitalisation,  significant  disability  or  incapacity,  any life-
threatening circumstance, or any other medically significant occurrence that are believed to be related to the
trial or interventions. All participating practice staff and physiotherapists will be asked to report to the CI as
soon  as  possible  any  identified  and  likely  related  serious  adverse  event  (SAE)  experienced  by  a  trial
participant. We have discussed this issue with the independent TSC and agreed that the potential harms of the
study are considered to be minimal and the stratified care information and matched treatment options are
considered  not  only  to  be  evidence-based  but  also  have  strong  clinical  community  endorsement  and
credibility. Any serious adverse events will be brought to the immediate attention of the trial team. The CI will
then assess whether the event was related to or resulted from any of the trial procedures or interventions,
according to the process laid out in Keele CTU’s SOPs. Any unexpected SAE considered to be related to the
trial  procedures  will  be  reported  to  the  main  Research  Ethics  Committee  by  the  CI  within  15  days  of
becoming aware of the event. In addition, all such events will be reported to the Trial Sponsor, Trial Steering
Committee and Data Monitoring Committee. 
Confidentiality and Anonymity
All information collected during the course of the trial  will  be kept  strictly confidential.   All  identifying
information will be anonymised before being used for analysis. Information will be held securely on paper
and managed electronically by Keele University through Keele CTU. Keele CTU complies with all aspects of
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the 1998 Data Protection Act. The trial data will be held on a database hosted on a secure server by Keele
CTU. All research staff involved in this study adhere to robust data security procedures and have explicit
duties of confidentiality. These practices are written into their employment contracts and are equivalent to the
duty  placed  on  NHS staff.  If  a  participant  withdraws  consent  from further  collection  of  data  their  data
collected  to  date  will  remain  on  file  and  will  be  included  in  the  final  study  analysis  unless  requested
otherwise.
Results
Recruitment to the trial commenced on 18th May 2018 and ended on 15th July 2019, after a recruitment
period of 14 months in 24 GP practices. It is anticipated that all follow-up and interview data collection will
be completed by February 2020. 
Discussion
This study protocol describes the detail of the STarT MSK trial, which aims to investigate the clinical and cost
effectiveness  of  stratified  primary  care  for  patients  with the  five  most  common MSK pain presentations
compared to usual non-stratified care. The intervention was designed to improve patient outcomes including
pain intensity, physical function and quality of life, and also clinician decision-making in order to reduce
treatment variability and improve adherence to best practice. This trial is the first attempt, as far as we know,
at testing a prognostic stratified care approach for primary care patients with MSK pain. The results of this
trial should be available by the summer of 2020.
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